- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05625919
A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)
A Phase Ⅰb/Ⅱ Multi-center Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Xiaohui Niu
- Phone Number: +86-1381132522
- Email: niuxiaohui@263.net
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing Jishuitan Hospital
-
Contact:
- Xiaohui Niu
- Phone Number: +861381132522
- Email: niuxiaohui@263.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 years or older, and Phase Ⅰb: Patients with histologically confirmed diagnosis of advanced soft tissue sarcomas (including malignant PEComa, accounting for at least 1/2) have failed standard treatment (disease progression or relapse or intolerance to chemotherapy, radiotherapy, targeted therapy, etc.) or lack effective treatment; Phase Ⅱ: Patients must have a histologically confirmed diagnosis of malignant PEComa that is either metastatic or locally advanced and for which surgery is not a recommended option.
[Malignant PEComas displaying 2 or more of the features of large size (> 5 cm), infiltrative growth, high nuclear grade, cellular necrosis, mitoses ≥1/50 high power field (HPF), or vascular invasion]
- At least 1 measurable lesion as defined by RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Life expectancy >3 months.
- Patient must have the following biological parameters levels at screening (without blood transfusion, EPO, G-CSF and other medical support within14 days prior to screening tests):
Blood tests: Absolute neutrophil count (ANC) ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L; Hemoglobin ≥90 g/L; Renal function tests: serum creatinine ≤1.5 x upper limit of normal (ULN); Liver function tests: Total bilirubin ≤1.5 x ULN (Patients with liver metastases, bile duct obstruction, or confirmed Gilbert syndrome: ≤ 3×ULN); AST and ALT ≤2.5 x ULN (≤5 x ULN if attributable to liver metastases); Blood clotting function tests: INR or PT ≤ 1.5 × ULN; APTT≤ 1.5 × ULN;
- Fasting serum triglycerides<300 mg/dL(3.42 mmol/L), fasting serum cholesterol < 350 mg/dL ( 9.07mmol/L; ).
- Fasting blood glucose (FPG) < 7.8 mmol/L and HbA1c < 8%.
- Women of child-bearing potential, or men whose partners are women of childbearing age must agree to use reliable contraceptive methods during the trial period and at least 6 months after the last administration; women of childbearing age must have a negative serum pregnancy test within 7 days prior to the first administration, should not be breast feeding.
- Patients must give informed consent to the study prior to the trial and voluntarily sign informed consent form.
Exclusion Criteria:
- Anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy within 4 weeks prior to the first dose of study drug, with the following special requirements:
Nitrosoureas (eg, carmustine, lomustine, etc.) or mitomycin C within 6 weeks prior to the first dose of study drug; Oral fluorouracils and small molecule targeted drugs within 2 weeks or 5 half-lives (whichever is longer) before the first dose of study drug; Traditional Chinese medicines with anti-tumor indications within 2 weeks prior to the first dose of study drug;
- Received other unmarketed clinical investigational drug within 4 weeks prior to the first dose of study drug.
- Major surgical procedures within 4 weeks prior to the first dose of study drug or not fully recovered from any previous invasive procedures.
- Received systemic glucocorticoids (prednisone > 10 mg/day or equivalent doses) or other immunosuppressive therapy within 2 weeks prior to the first dose of the study drug [with the following exceptions: treatment with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; short-term use of glucocorticoids for prophylaxis (eg, prevention of contrast allergy)].
- Infection that required systemic anti-infective therapy (oral or IV) within 2 weeks before enrollment.
- Inactivated or live attenuated vaccine or novel coronavirus vaccine within 30 days before the first dose.
- Use of strong inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study drug, or requiring concomitant treatment during the study.
- History of other malignancies within 5 years prior to the first dose of the study drug, except in the following cases: cured basal cell or squamous cell skin cancer, superficial bladder cancer, prostatic carcinoma in situ, carcinoma in situ of the cervix, breast carcinoma in situ, etc., or locally curable cancer that has been disease-free for 5 years;
- Liver-directed therapy is required within 2 months of enrollment. Prior treatment with radiotherapy (including radio-labeled spheres and/or cyberknife, hepatic arterial embolization (with or without chemotherapy) or cyrotherapy/ablation) is allowed if these therapies does not affect the areas of measurable disease being used for this protocol.
- History of serious cardiovascular disease, such as severe heart rhythm or conduction abnormalities (ventricular arrhythmias requiring clinical intervention, grade Ⅱ or Ш atrioventricular block, etc.). History of myocardial infarction, unstable angina, heart failure, New York College of Cardiology (NYHA) grade Ⅱ and above, and coronary artery bypass surgery within 6 months before the first dose of the study drug; Left ventricular ejection fraction (LVEF) < 50%, QTcF > 450 msec (male) or female QTcF > 470 msec (female), etc.
- Unresolved toxicity from prior anti-tumor therapy greater than Grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.(except for alopecia and any other toxicities that have no safety risk judged by the investigator).
- Known active uncontrolled or symptomatic central nervous system (CNS) metastases, or other evidence of uncontrollable central nervous system metastases or meningeal metastases that not eligible for inclusion determined by the investigator.
- Hydrothorax, ascites or pericardial effusion with clinical symptoms or required symptomatic treatment.
- Patients with angiomyolipoma(AML) or lymphangioleiomyomatosis (LAM).
- History of serious lung disease, such as interstitial lung disease and/or pneumonitis, or pulmonary hypertension, or pre-existing severely impaired lung function.
- Pre-existing thyroid abnormality is allowed provided thyroid function can be controlled with medication.
- Known hypersensitivity or intolerance to any ingredient in the study drug.
- History of autoimmune disease (except tuberous sclerosis), immunodeficiency, including positive HIV test, or other acquired or congenital immunodeficiency disease, or history of organ transplantation.
- Active Hepatitis B or Hepatitis C, or active syphilis infection Active Hepatitis B: HBsAg-positive with HBV DNA titer ≥ 1 × 10^3 IU/mL; Patients are eligible for enrollment if they are HBsAg positive with peripheral blood HBV-DNA < 1 × 10^3 IU/mL if, in the opinion of the investigator, the patient's chronic hepatitis B is in a stable phase and does not increase the subject's risk.
Active Hepatitis C: HCV antibodies -positive with HCV RNA-positive; Active syphilis infection: Treponema pallidum antibodies (RPR or TRUST)-positive or presence of syphilis infection requiring systemic therapy.
- Severe concomitant diseases that endanger patient safety, interfere the compliance of the study procedure (such as uncontrollable hypertension, active gastrointestinal bleeding, etc.) or other reasons that make the patient inappropriate for entry into this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sirolimus for Injection (Albumin-bound)
Sirolimus for injection (Albumin-bound) will be administered intravenously on day 1and day 8 every 21 days (a cycle).
|
Sirolimus for injection (Albumin-bound), intravenously, once a week, 21 days per cycle (two weeks-on and one week-off)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AE and SAE occurrence and frequency in phase Ⅰb
Time Frame: Up to 2 years
|
Up to 2 years
|
Dose-limiting toxicities (DLT)
Time Frame: Cycle 1 (Up to 21 days)
|
Cycle 1 (Up to 21 days)
|
Maximum tolerated dose (MTD)
Time Frame: Cycle 1 (Up to 21 days)
|
Cycle 1 (Up to 21 days)
|
Recommended phase 2 dose (RP2D)
Time Frame: Cycle 1 (Up to 21 days)
|
Cycle 1 (Up to 21 days)
|
Overall response rate (ORR) in phase Ⅱ
Time Frame: Up to 2 years
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free Survival (PFS)
Time Frame: Up to 2 years
|
Up to 2 years
|
Overall survival (OS)
Time Frame: Up to 2 years
|
Up to 2 years
|
Disease Control Rate (DCR)
Time Frame: Up to 2 years
|
Up to 2 years
|
Duration of Response (DOR)
Time Frame: Up to 2 years
|
Up to 2 years
|
Overall response rate (ORR) in phase Ⅰb
Time Frame: Up to 2 years
|
Up to 2 years
|
AE and SAE occurrence and frequency in phase Ⅱ
Time Frame: Up to 2 years
|
Up to 2 years
|
Area under the plasma concentration versus time curve (AUC)
Time Frame: Up to 2 years
|
Up to 2 years
|
Peak Plasma Concentration (Cmax)
Time Frame: Up to 2 years
|
Up to 2 years
|
Peak time (Tmax)
Time Frame: Up to 2 years
|
Up to 2 years
|
Terminal half-life (t½)
Time Frame: Up to 2 years
|
Up to 2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Perivascular Epithelioid Cell Neoplasms
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- HB1901-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)
-
Aadi Bioscience, Inc.CompletedMalignant PEComaUnited States
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Novartis PharmaceuticalsWithdrawnMalignant PEComa (Perivascular Epithelioid Cell Tumors)Spain
-
University Hospital, Strasbourg, FranceRecruitingPerivascular Epithelioid Cell Tumor, MalignantFrance
-
University Hospital, Strasbourg, FranceUnknown
-
University Hospital, BordeauxNational Cancer Institute, France; Ministry for Health and Solidarity, FranceCompleted
-
Institut Claudius RegaudRecruitingSoft Tissue Sarcoma | Perivascular Epithelioid Cell Neoplasms | Epithelioid Sarcoma | Alveolar Soft Part Sarcoma | Desmoplastic Small Round Cell Tumor | Clear Cell Sarcoma | Sclerosing Epithelioid Fibrosarcoma | Low Grade Fibromyxoid Sarcoma | Malignant Solitary Fibrous Tumors | Epithelioid HemangioendotheliomaFrance
-
Fox Chase Cancer CenterNovartis PharmaceuticalsTerminatedSporadic Angiomyolipomas (AMLs)United States
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingAdvanced Malignant TumorChina
-
Shanghai Junshi Bioscience Co., Ltd.Sponsor GmbHNot yet recruitingAdvanced Malignant TumorChina
Clinical Trials on Sirolimus for Injection (Albumin Bound)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingAdvanced Solid TumorsChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingMalignant Solid Tumors
-
China Medical University, ChinaRecruiting
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.UnknownNon-Small Cell Lung CancerChina
-
Sun Yat-sen UniversityShanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.RecruitingEsophageal Small Cell CarcinomaChina
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Peking UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingGastric Cancer | Adenocarcinoma of Esophagogastric JunctionChina
-
Fuzhou General HospitalUnknownNasopharyngeal CarcinomaChina
-
Shanghai Yizhong Pharmaceutical Co., Ltd.RecruitingMetastatic Breast Cancer (MBC)China